Results 241 to 250 of about 61,173 (287)
Some of the next articles are maybe not open access.
Hematology/Oncology Clinics of North America, 1992
The general characteristics of antithrombin III (AT III) concentrates available in the United States are described in this article. The effectiveness of AT III concentrates in the prevention and treatment of thrombotic episodes in patients with hereditary AT III deficiency are summarized, and the use of this product in various conditions with acquired ...
openaire +2 more sources
The general characteristics of antithrombin III (AT III) concentrates available in the United States are described in this article. The effectiveness of AT III concentrates in the prevention and treatment of thrombotic episodes in patients with hereditary AT III deficiency are summarized, and the use of this product in various conditions with acquired ...
openaire +2 more sources
Blood Reviews, 1988
A moderate reduction of plasma antithrombin activity is an uncommon but clinically important cause of severe thromboembolic disease. In recent years the molecule responsible for the major part of this activity (antithrombin III) has been extensively characterised and the mode of inheritance of familial deficiencies worked out.
openaire +2 more sources
A moderate reduction of plasma antithrombin activity is an uncommon but clinically important cause of severe thromboembolic disease. In recent years the molecule responsible for the major part of this activity (antithrombin III) has been extensively characterised and the mode of inheritance of familial deficiencies worked out.
openaire +2 more sources
New antithrombin‐based anticoagulants
Medicinal Research Reviews, 2003AbstractClinically used anticoagulants are inhibitors of enzymes involved in the coagulation pathway, primarily thrombin and factor Xa. These agents can be either direct or indirect inhibitors of clotting enzymes. Heparin‐based anticoagulants are indirect inhibitors that enhance the proteinase inhibitory activity of a natural anticoagulant ...
openaire +2 more sources
Risk of Venous Thrombosis in Antithrombin Deficiency: A Systematic Review and Bayesian Meta-analysis
Seminars in Thrombosis and Hemostasis, 2018N. Croles +4 more
semanticscholar +1 more source
Annales de biologie clinique, 1987
The in vivo regulation of coagulation is mainly controlled by plasma inhibitors in which antithrombin III (AT III) plays an importance role. AT III is a glycoprotein which inhibits all serine proteases, except factor, VIIa, generated during the coagulation process. The proteases are inactivated by formation of an equimolecular complex and this reaction
C, Boyer-Neumann, M, Wolf, M J, Larrieu
openaire +1 more source
The in vivo regulation of coagulation is mainly controlled by plasma inhibitors in which antithrombin III (AT III) plays an importance role. AT III is a glycoprotein which inhibits all serine proteases, except factor, VIIa, generated during the coagulation process. The proteases are inactivated by formation of an equimolecular complex and this reaction
C, Boyer-Neumann, M, Wolf, M J, Larrieu
openaire +1 more source
High levels of latent antithrombin in plasma from patients with antithrombin deficiency
Thrombosis and Haemostasis, 2017M. E. de la Morena-Barrio +14 more
semanticscholar +1 more source